NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLa ...

Core Insights - Psyence Biomedical Ltd. has established a Scientific Advisory Board (SAB) to enhance its expertise in psilocybin research and clinical trial design [1][3] - Dr. Albert P. Garcia-Romeu, a prominent researcher in psychedelics, will chair the SAB, bringing significant experience in psilocybin clinical trials [2][3] - The company is advancing its Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and is preparing for a second indication in Alcohol Use Disorder [3][4] Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, specifically nature-derived psilocybin [4] - The company aims to address unmet needs in mental health disorders, particularly in the context of Palliative Care [4] - Psyence is the first life science biotechnology company developing psilocybin-based psychedelic medicine to be listed on Nasdaq [4] Research and Development - The SAB will assist in designing the Phase III program for Adjustment Disorder while also preparing for Alcohol Use Disorder development [3] - Dr. Garcia-Romeu's involvement is expected to enhance the company's research capabilities in areas that have been largely overlooked by the pharmaceutical industry [4]